Edison, N.J.-based Hackensack Meridian Health announced Dec. 4 an investment in Adaptive Phage Therapeuticals, a clinical-stage company developing precision treatments for multidrug-resistant superbugs.
The funding, Hackensack Meridian’s third investment in an external company, was provided through the health system’s Bear’s Den innovation program. The Bear’s Den incubator was launched in 2017 and comprises a panel of healthcare executives, physicians, venture capitalists and more to vet proposals from healthcare entrepreneurs.
“At the Center for Discovery and Innovation, we have been highly engaged in creating novel solutions to prevent and overcome deadly multidrug-resistant infections,” said David Perlin, PhD, chief scientific officer and senior vice president of the Hackensack Meridian-based center. “This is a burgeoning global threat. We welcome the investment and collaboration with partners such as APT, who are working alongside us to combat it.”